SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.

Author:

Andre Fabrice1,Campone Mario2,Ciruelos Eva M.3,Iwata Hiroji4,Loibl Sibylle5,Rugo Hope S.6,Wilke Celine7,Mills David8,Chol Marie8,Longin Anne-Sophie9,Juric Dejan10

Affiliation:

1. Institut Gustave Roussy, Villejuif, France;

2. Cancer Institute of the West (ICO), Centre René Gauducheau, Medical Oncology Department, Saint-Herblain, France;

3. Hospital Universitario 12 De Octubre, Madrid, Spain;

4. Aichi Cancer Center Hospital, Nagoya, Japan;

5. German Breast Group, Neu-Isenburg, Germany;

6. University of California, San Francisco, San Francisco, CA;

7. Medigene AG, 81247, Munich, Germany;

8. Novartis Pharma AG, Basel, Switzerland;

9. Novartis Pharma S.A.S., Paris, France;

10. Massachusetts General Hospital Cancer Center, Boston, MA;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3